Inadequate medical isotope reach crisis fractions
Lack of adequate isotopes will be an important subject of discussion for the experts convening at the Society of Nuclear Medicine (SNM) meeting in Toronto on the coming weekend.
Pharma
Cadila expects Rs 100-cr revenue from Policap
Ahmedabad-based Cadila Pharmaceuticals on Saturday said it is expecting a revenue of INR 100 crore from the sale of its patented combination drug, Policap, which it expects to launch by the middle of next month.
Pharma cos recast European operations to protect margins
Indian pharmaceutical companies are reworking their strategies for Europe to cope with the intense pressure on drug prices because of changing trends in the key market.
Ranbaxy starts phase III study of anti-malaria drug
Ranbaxy Laboratories announced that its new anti-malarial combination drug is now undergoing final stage of development. In its press-release, the company said that the drug is targeted at patients in developing countries with the aim of significantly improving upon the conventional options available for the treatment of P falciparum malaria.
Wockhardt settles Entacapone patent and license agreement with Orion Corporation
Wockhardt Limited have uted the Entacapone patent settlement and license agreement with Orion Corporation in US.
TAKE Solutions adds Cadila Pharmaceuticals to their growing list of clients
Cadila Pharmaceuticals chooses TAKE Solutions for their PharmaReady eCTD, SPL and PPM software.
Arch Pharmalabs gets verification mark from USP (PIVP)
Arch Pharmalabs Ltd. received a new verification mark for a drug substance from US Pharmacopeia (USP) under the Pharmaceutical Ingredient Verification Program (PIVP) at their manufacturing facility in Gurgaon, India.
Marck Biosciences foray into Singapore and Malaysia
Marck Biosciences, a leading manufacturer and marketer of sterile dosages pharma products and Blow-Fill-Seal specialist, today announced its plan to enter the Singapore and Malaysian market.
DMARDs likely to dominate the therapy market for Rheumatoid Arthritis – Frost and Sullivan
In spite of new drugs available for treating Rheumatoid Arthritis, DMARDs are likely to remain as the preferred first line of therapy.
New norms for MNC drug prices
In a move that would prevent MNCs such as GlaxoSmithKline (GSK), Eli Lilly, Roche and Pfizer from selling their drugs at a huge premium in India, the government may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes, arthritis, obesity, cancer and heart diseases.
Unbranded generic drugs to be sold at people
The Centre is planning to open 40
Industry to supply low cost medicines to generic stores
The department of pharmaceuticals (DoP) has received 76 applications from domestic drug makers who are interested in supplying generic medicines at a lower price to the generic drug stores (Jan Aushadhi Stores) recently being set up by the government in several states.
TCG Lifesciences conferred with
TCG Lifesciences Limited has been conferred with
